Condition
Chemoembolization
Total Trials
3
Recruiting
0
Active
0
Completed
2
Success Rate
66.7%-20% vs avg
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 54/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
66.7%
-19.8% vs benchmark
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results67% success
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
P 3 (1)
Trial Status
Completed2
Terminated1
Trial Success Rate
66.7%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT03474354Completed
DC Bead LUMI (TM) Loaded With Doxorubicin for Intermediate Hepatocellular Carcinoma (HCC)
NCT02147301Not ApplicableTerminated
TACE Using Doxorubicin-eluting Beads for Patients With HCC and Marginal Hepatic Reserve
NCT00652587Phase 3Completed
Hepatectomy With or Without Transcatheter Arterial Chemoembolization for Stage IIIA Hepatocellular Carcinoma
Showing all 3 trials